Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per
CERO THERAPEUTICS HOLDINGS, INC.
Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)
1 trial -
Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules
Novartis Pharmaceuticals
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
1 trial -
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Vanda Pharmaceuticals Netherlands B.V.
Autism Spectrum Disorder
1 trial -
Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules
Lacuna Pharma Pty Ltd
Newly diagnosed primary glioblastoma multiforme (ndGBM)
1 trial -
Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Relapsed/refractory primary central nervous system lymphoma
1 trial -
The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.
Lacuna Pharma Pty Ltd
treatment-resistant schizophrenia (TRS)
1 trial -
The placebo product consists of a soft capsule similar to the ones containing the active substance, VESSEL® 250 ULS capsule molli
Fondazione Telethon ETS
Prevention of recurrence after a first episode of Venous Thromboembolism (VTE)
1 trial -
Treatment of TongBi Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
Troriluzole, Placebo for BHV-4157 capsules, 100mg, 140mg, Troriluzole
Lacuna Pharma Pty Ltd
Obsessive Compulsive Disorder
1 trial -
VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
Valbenazine, Valbenazine, Placebo for valbenazine capsules
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
White opaque capsule filled with a white to off- white powder, eRapa
Biodexa Pharmaceuticals Plc
Familial adenomatous polyposis (FAP)
1 trial -
XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules
Hoffmann-La Roche
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
1 trial -
XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)
Bristol-Myers Squibb Australia Pty Ltd
Non small cell lung cancer (NSCLC)
1 trial -
XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek 100 mg hard capsules, Rozlytrek, Rozlytrek 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek
Hoffmann-La Roche
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
1 trial -
Xanomeline and Trospium Chloride Capsules
Bristol-Myers Squibb Australia Pty Ltd
Schizophrenia
1 trial -
Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets
Ningbo Cancer Hospital
Metastatic Prostate Cancer
1 trial -
Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg
Pfizer Australia Pty Ltd
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
1 trial -
Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection
Ningbo Cancer Hospital
Castration resistant prostate cancer patients metastatic to bone.
1 trial -
Xtandi - 40 mg soft capsules, Xtandi - 40 mg soft capsules, TALAZOPARIB, Xtandi 40 mg soft capsules, TALAZOPARIB, Xtandi - 40 mg soft capsules, Talazoparib placebo
Pfizer Australia Pty Ltd
Metastatic Castration-sensitive Prostate Cancer
1 trial -
YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Relapsed/Refractory Follicular Lymphoma
1 trial -
Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, ELRANATAMAB, Zelvina 10 mg hard capsules, Privigen 100 mg/ml solution for infusion
Pfizer Australia Pty Ltd
Multiple Myeloma
1 trial -
Zelvina 25 mg hard capsules, Dexamethasone 0.5mg Tablets, Zelvina 15 mg hard capsules, ELRANATAMAB, Privigen 100 mg/ml solution for infusion, Zelvina 2.5 mg hard capsules, Zelvina 10 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Nodexon 20 mg tabletid, DARZALEX 1800 mg solution for injection, Nodexon 20 mg tabletės, Nodexon 20 mg tabletes, Nodexon 20 mg tabletės, Dexamethasone 4 mg tablets, Zelvina 5 mg hard capsules
Pfizer Australia Pty Ltd
Multiple myeloma
1 trial -
Zelvina 25 mg hard capsules, Zelvina 10 mg hard capsules, Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 20 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion
Incyte
Diffuse large B-cell lymphoma (DLBCL)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources